BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Announces Publication of New Research Demonstrating Increased Lymphatic Transport with Glyph Platform.
BOSTON--(BUSINESS WIRE)--PureTech's Deupirfenidone Slowed Lung Function Decline in People w/ IPF, Achieving the Primary & Key Secondary Endpoints in ELEVATE IPF Phase 2b Trial.
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024.
BOSTON--(BUSINESS WIRE)--PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting.
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.